Abstract
BackgroundThe plant Kingiodendron pinnatum (DC.) Harms, belonging to the family Fabaceae is endemic to the Western Ghats of India and is commonly used for various ailments, especially by the tribes. K. pinnatum is occasionally used as a substitute for Saraca asoca in Asokarishta, a well-known uterine tonic in Ayurveda. Recent studies revealed a pharmacological similarity between the plants. S. asoca is reported to have anti-cancer properties, but there are no reports on K. pinnatum except for antioxidant and antimicrobial activities. Therefore, the study is aimed to investigate the anticancer potential of the plant.MethodsCytotoxicity of methanolic bark extract of the plant was analysed on different cancer cell lines by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Dalton's lymphoma ascites (DLA) cell-induced solid and Ehrlich ascites carcinoma (EAC) cell-induced ascites tumour models in mice were used to study the antitumor potential. Phytochemical screening of the extract was also performed.ResultsThe extract was found cytotoxic to DLA, EAC, HCT15, MDA-MB-231, T47D and PC3 with inhibitory concentration (IC50) values of 50.09, 74.74, 67.02, 119.22, 149.04 and 194.5 μg/mL, respectively. In the solid tumour model, a significant (P < 0.001) reduction in tumour weight of 0.7 ± 0.15 g was observed in 500 mg/kg b.wt. extract treated group compared to the control group (3.6 ± 0.24 g) by oral administration for 30 days. In the ascites tumour model, a high survival rate of 28.2 ± 8.72 days (P < 0.01) was found by the extract treatment compared to the control animals. Phytochemicals like alkaloids, flavonoids, phenols, phytosterols, saponins, tannins, steroids and terpenoids were detected in the extract.ConclusionResults obtained by the cytotoxic and anti-tumour studies revealed the anticancer potential of K. pinnatum. The plant exhibits more cytotoxicity towards cancer cell lines of the reproductive system such as the breast and prostate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
